Monthly Archives: December 2019

INVESTOR ALERT – Green Dot Corp (GDOT) – Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 17, 2020

NEW YORK, NY / ACCESSWIRE / December 23, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Green Dot Corp ("Green Dot" or the Company") (NASDAQ:GDOT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Green Dot securities between May 9, 2018 and November 7, 2019, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/gdot.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Green Dot's strategy to attract "high-value" long-term customers was at the expense of "one and done" customers; (2) Green Dot's "one and done" customers represented a significant source of revenues in its legacy segment; (3) consequently, Green Dot's strategy was self-sabotaging; and (4) as a result of the foregoing, Defendants' statements about its business and operations were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/gdot or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Green Dot you have until February 17, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 571124

Parnell Pharmaceuticals Holdings Ltd Announces Business Update

Parnell announces 2019 year-to-date revenue growth of 9% over the first 9 months of 2018, start of work on its new 2019 CMO contract, and updates to 2019 financial results.

SYDNEY, AUSTRALIA / ACCESSWIRE / December 23, 2019 / Parnell Pharmaceuticals Holdings Ltd (OTC PINK:PARNF) today announced: ongoing 2019 revenue growth of 9% to September 30 compared with the first 9 months of 2018; commencement of technical work to establish the first of three new contract manufactured products; and updated financial results to the end of Quarter 3, 2019.

Brad McCarthy, CEO and Executive Director, said, "Our established business units continue to perform strongly through Quarter 3 of 2019. Overall, revenues grew 9% to September 30 compared to the corresponding period in 2018. This growth reflects the consistently sound performance of our Production Animal and CMO teams in securing and delivering customer orders and meeting market expectations."

Mr. McCarthy continued, "The initial technical transfer fee on the newest CMO contract has been received and our technical work on the first of the three proposed products is now well under way. We anticipate receiving the second customer technology transfer fee on the second product early in 2020 after which the technical transfer process will likewise begin at our Sydney facility. We are well into discussions with the customer on timing for the third product under the agreement, which is currently proposed for the second half of 2020."

"The achievement of zero 483 observations at the mid-2019 FDA routine re-inspection of our sterile manufacturing facility has proven very positive for our industry positioning and reputation, having increased the level of inbound enquiry from potential CMO customers seeking a highly reliable FDA-approved product source with an established track record of excellence," Mr. McCarthy continued.

Mr. McCarthy updated the Company's financial results for the first 9 months of 2019 year comprising: revenue of $21.8 million compared to $20.0 million for the corresponding period in 2018, and a $0.8 million increase in operating expenses from increased investment in US Production and Manufacturing, combining to deliver a $0.1 million increase over the same period in 2018 in Earnings Before Interest, Tax, Depreciation, Amortization and Other Income/(Expense) (EBITDAOI) to $5.4 million.

Business Segment Performance

Unless otherwise specified, all amounts are presented in Australian Dollars (AUD).​

"Sales of our proprietary products and CMO product revenues to the end of Quarter 3 grew 7% over the corresponding period in 2018," Mr. McCarthy stated. "With the recent inception of our newest CMO contract, technology transfer revenue from new CMO contracts increased in the third quarter of 2019 to be year-to-date $0.5 million up on the same period in 2018."

"Production Animal sales to Quarter 3, 2019 increased 3% over the corresponding period in 2018 to $10.4 million. As we have introduced new Territory Managers in the US Production Animal business during the first nine months of 2019 the sales response has been encouraging from their presence in the field, especially in Quarter 3 where in-market sales grew 18% over the same quarter in 2018," Mr. McCarthy said. "US Companion Animal sales continue to track slightly behind plan, with the commensurate lower expense base minimising the effect on 2019 profit projections for this business unit overall. Both our Australian Companion business and Australia and New Zealand Production Animal businesses have continued strong growth again during Quarter 3, 2019."

"Our Board has now restated provisional full-year 2019 guidance at 8-11% revenue growth to $28.5 – $29.5 million, and an EBITDAOI range of $6.5 – $7.5 million, over our 2018 results of $26.5 million revenue and $6.1 million," Mr. McCarthy said. "As foreshadowed in our previous release, a delay in the commencement of our new contract manufacturing agreement and the associated effect of some CMO revenue pushing into 2020 resulted in a timing impact on our full year 2019 guidance."

Corporate Updates

Dr. Alan Bell, Executive Director and Chairman of the Board, said "The breadth of our CMO and new product development discussions widened again during Quarter 3. With in-house technical work now well under way on our newest CMO contract, we are currently engaged with prospective new CMO and development partners aiming to add further contracts in 2020."

Dr. Bell continued, "We have continued to make good progress on the human generic project. We are excited by the latest achievements and remain positive on the prospects for future success in this franchise."

"On the capital front, the Board of Directors recently appointed advisors to assist the Company in seeking the appropriate level of growth capital for business expansion projects in 2020 and beyond. In effect the Board is seeking to build on the priority initiatives of the past 2 years in creating sound business growth that enhances asset and shareholder value," Dr. Bell said. "We expect to provide further updates on this process in coming months."

"An employment claim by our former CEO following his dismissal in 2017 and our counter-suit were tried together in the Federal Court of Australia on October 2019. We now await judgement, which we anticipate will be handed down in 2020," Dr. Bell concluded.

Commercial Highlights to 30 September 2019

Unless otherwise specified, all amounts are presented in Australian Dollars (AUD).

Regarding the Company's financial performance at the end of Quarter 3 2019, your directors report the following achievements:

Total revenue was $21.8 million for the nine months ended September 30, 2019, being $1.8 million (9%) up over the same period in 2018.

Our operating segments performed as follows:

Production Animal sales of $10.4 million globally representing an increase of $0.4 million (3%) over the same period in 2018, comprised of: 16% growth in Australia and New Zealand Production, 38% growth in Rest of World Production and flat in US Production Animal due to year on year timing of orders into distribution partners. The performance in our key markets (USA, Australia and New Zealand) continues to demonstrate our strong market positioning, especially in those regions in which we have an established presence. As we continue to on-board sales staff in additional territories in the US we have been very pleased with the progress made during the quarter with 18% growth in our US Production business alone in Quarter 3. Our digital asset, mySYNCH, continues to build significant momentum in 2019 with an additional 2% of the total US dairy cows added during the three months to September 30, 2019.

Companion Animal sales of $2.4 million for the nine months ended September 30, 2019 were flat compared to the same period in 2018. US Companion Animal was down 10% for the period, with a similar reduction in cost base of this business segment delivering a small increase in year on year contribution. The Australian Companion Animal business continues to grow, posting 6% growth through the end of Quarter 3, 2019, after recording 11% full-year growth in 2018.

Contract Manufacturing revenues for the nine months ended September 30, 2019 were $9.0 million, an 18% increase over revenues of $7.7 million for the same period in 2018. The total for the first three quarters of 2019 comprised technology transfer and milestone revenues of $2.9 million, compared to $2.5 million for the same period in 2018, and batch delivery revenues of $6.0 million, a 17% increase compared to $5.2 million in 2018.

Operating expenditures across the business increased by $0.8 million in the period to $8.6 million, compared to $7.8 million for the same period in 2018.

As a result, EBITDAOI increased $0.1 million to $5.4 million for the nine months ended September 30, 2019, compared to $5.3 million for the same period in 2018.

2019 Guidance

Unless otherwise specified, all amounts are presented in Australian Dollars (AUD).​

2019 guidance is lowered to $28.5 – $29.5 million in sales, an 8 – 11% increase over 2018 revenue, and an EBITDA range of $6.5 – $7.5 million due to postponement of some contracted technology transfer income and CMO product sales until early 2020.

Financial Results for the six months ended 30 September 2019:

Unless otherwise specified, all amounts are presented in Australian Dollars (AUD).​

Total revenue was $21.8 million for the nine months ended September 30, 2019, a 9% increase compared to $20.0 million for the same period in 2018. A detailed description of the revenue performance by business unit is provided above.

Expenses:

Cost of Sales for the period ended September 30, 2019 were $7.8 million, compared to $6.9 million for the comparable period in 2018. Gross margin as a percentage of revenue, using a Cost of Goods Sold – Product basis, was 84% in 2019 compared to 86% in 2018, due to a slight mix variance in 2019 as our CMO product revenues continue to grow as a proportion of our total business.

Selling and Marketing expenses increased by $0.6 million, or 15%, to $4.4 million for the period ended September 30, 2019 compared to the same period in 2018, primarily from the increase in US Production Animal sales and marketing presence as we continue to establish new territories in this region.

Regulatory and R&D spending for the quarter was $0.6 million, an increase of $0.2 million over the same period in 2018, primarily due to increased government regulatory fees.

Administration expenses were $3.5 million in 2019, flat with the same period in 2018.

Finance costs of $6.3 million for the nine months ended September 30, 2019 increased by $0.8 million over the same period in 2018, due to the difference in structure of our senior debt facility compared to the previous facility; however the cost of the new facility is substantially lower over the full term of the loan.

Other Income/(Expense) for the nine months ended September 30, 2019 was income of $2.0 million compared to income of $3.2 million for the same period in 2018. This reduction in income was entirely due to foreign exchange movements between the Australian dollar and the US dollar for the period. $0.1 million of non-recurring legal costs were recorded in 2019.

Earnings Before Interest, Tax, Depreciation, Amortization and Other Income/(Expense) (EBITDAOI) & Total Comprehensive Loss:

Earnings Before Interest, Tax, Depreciation, Amortization and Other Income/(Expense) for the nine months ended September 30, 2019, increased by $0.1 million to $5.4 million compared to $5.3 million for the same period in 2018.

Total comprehensive loss for the nine month period ended September 30, 2019 was $5.1 million compared to $4.0 million in 2018, predominately due to a reduction in other income associated with foreign exchange movements, offset by a decrease in foreign currency translation reserve expenses.

The unaudited Financial Statements for the nine months ended September 30, 2019 compared to prior year are presented below.

About Parnell

Parnell (OTC: PARNF) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal and human health solutions. Parnell is a technology and clinical science leader in dairy reproduction, marketing its proprietary brands estroPLAN and GONAbreed via its dedicated sales force and digital technology mySYNCH in the USA and Australia-New Zealand, and via distributors in other markets. Parnell has a rapidly growing contract manufacturing business supplying industry majors with specialized sterile injectable products. Recently, Parnell leveraged its novel intellectual property position in the Pentosan Polysulfate drug class to address the human market through a new contract with a major global human health company. In companion animal, Parnell manufactures and markets its proprietary canine osteoarthritis brands Zydax and Glyde.

For more information on the company and its products, please visit www.parnell.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of the U.S. Private Securities Reform Act of 1995. Words such as "may," "anticipate," "estimate," "expects," "projects," "intends," "plans," "develops," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. Forward-looking statements represent management's present judgment regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding Parnell's research and development activities, its ability to conduct clinical trials of product candidates and the results of such trials, as well as risks and uncertainties relating to litigation, government regulation, economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on third parties, and other factors, including those described in Parnell's Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on March 31, 2017, along with its other reports filed with the SEC. In light of these assumptions, risks, and uncertainties, the results and events discussed in any forward-looking statements contained in this press release might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Parnell is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise.

###

For more information, contact:
Parnell Pharmaceuticals Holdings
Brad McCarthy
Phone+61 2 9667 4411
Email: brad.mccarthy@parnell.com

Consolidated Statements of Comprehensive Loss (Unaudited)

 

 
For the Nine – Months Ended
September 30,
 

 

 
2019
($AUD)
 
 
2018
($AUD)
 

Revenue

 
 
21,759,728
 
 
 
19,982,608
 

Cost of goods sold

 
 
(7,782,072
)
 
 
(6,876,228
)

Gross Margin

 
 
13,977,656
 
 
 
13,106,380
 

Selling and Marketing expenses

 
 
(4,418,763
)
 
 
(3,845,743
)

Regulatory, R&D expenses

 
 
(654,315
)
 
 
(443,928
)

Administration Expenses

 
 
(3,524,290
)
 
 
(3,488,396
)

E.B.I.T.D.A.O.I.

 
 
5,380,288
 
 
 
5,328,313
 

 

 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 

Depreciation and Amortization expenses

 
 
(2,296,723
)
 
 
(1,752,227
)

Finance costs

 
 
(6,322,051
)
 
 
(5,496,174
)

Other income/(expense)

 
 
1,860,963
 
 
 
3,192,623
 

(Loss)/profit before income tax

 
 
(1,377,523
)
 
 
1,272,535
 

Income tax expense

 
 
0
 
 
 
0
 

(Loss)/profit for the year

 
 
(1,377,523
)
 
 
1,272,535
 

 

 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 

Foreign currency translation

 
 
(3,745,130
)
 
 
(5,256,809
)

Total comprehensive loss for the year

 
 
(5,122,653
)
 
 
(3,984,274
)

Consolidated Balance Sheets (Unaudited)

 

 

30 September 2019

AUD$

 
 

31 December 2018

AUD$

 

ASSETS

 
 
 
 
 
 

CURRENT ASSETS

 
 
 
 
 
 

Cash and cash equivalents

 
 
3,681,772
 
 
 
4,400,647
 

Trade and other receivables

 
 
4,465,121
 
 
 
1,739,466
 

Inventories

 
 
2,617,746
 
 
 
3,194,154
 

Prepayments

 
 
591,980
 
 
 
444,313
 

TOTAL CURRENT ASSETS

 
 
11,356,619
 
 
 
9,778,580
 

NONCURRENT ASSETS

 
 
 
 
 
 
 
 

Trade and other receivables

 
 
68,166
 
 
 
60,200
 

Property, plant and equipment

 
 
15,043,365
 
 
 
10,593,307
 

Intangible assets

 
 
13,561,078
 
 
 
13,052,325
 

TOTAL NONCURRENT ASSETS

 
 
28,672,609
 
 
 
23,705,832
 

TOTAL ASSETS

 
 
40,029,228
 
 
 
33,484,412
 

 

 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 

LIABILITIES

 
 
 
 
 
 
 
 

CURRENT LIABILITIES

 
 
 
 
 
 
 
 

Trade and other payables

 
 
7,166,502
 
 
 
5,974,086
 

Borrowings

 
 
15,345
 
 
 
9,718
 

Provision for employee benefits

 
 
882,851
 
 
 
780,970
 

TOTAL CURRENT LIABILITIES

 
 
8,064,698
 
 
 
6,764,774
 

NONCURRENT LIABILITIES

 
 
 
 
 
 
 
 

Trade and other payables

 
 
4,610,457
 
 
 
62,319
 

Borrowings

 
 
50,762,304
 
 
 
45,032,806
 

Provision for employee benefits

 
 
240,312
 
 
 
152,127
 

TOTAL NONCURRENT LIABILITIES

 
 
55,613,073
 
 
 
45,247,252
 

TOTAL LIABILITIES

 
 
63,677,771
 
 
 
52,012,026
 

NET ASSETS

 
 
(23,648,543
)
 
 
(18,527,614
)

 

 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 

EQUITY

 
 
 
 
 
 
 
 

Ordinary shares

 
 
63,515,902
 
 
 
63,515,902
 

Share-based compensation reserve

 
 
3,251,515
 
 
 
3,251,515
 

Reserves

 
 
(10,766,096
)
 
 
(7,022,336
)

Accumulated losses

 
 
(79,649,864
)
 
 
(78,272,695
)

TOTAL EQUITY

 
 
(23,648,543
)
 
 
(18,527,614
)

 
 
 
 
 
 
 
 
 

SOURCE: Parnell Pharmaceuticals Holdings

ReleaseID: 571147

Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation of Sterling Bancorp, Inc. (SBT)

NEW YORK, NY / ACCESSWIRE / December 23, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sterling Bancorp, Inc. ("Sterling" or the Company") (NASDAQ:SBT). Investors who purchased Sterling securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/sbt.

The investigation concerns whether Sterling and certain of its officers and/or directors have violated federal securities laws.

On December 9, 2019, Sterling Bancorp disclosed that its subsidiary, Sterling Bank and Trust, FSB, had suspended its Advantage Loan program due to an ongoing internal review of documentation on past loans and due to an implementation of "systems and controls to ensure the Bank's policies and procedures are followed on loans originated under the program." On this news, Sterling Bancorp's stock price fell $2.16 per share, or 22.86%, to close at $7.29 per share on December 9, 2019.

If you are aware of any facts relating to this investigation, or purchased Sterling shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/sbt. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 571128

CINCINNATI BELL INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

WILMINGTON, DE / ACCESSWIRE / December 23, 2019 / Rigrodsky & Long, P.A.:

Do you own shares of Cincinnati Bell Inc. (NYSE:CBB)?
Did you purchase any of your shares prior to December 23, 2019?
Do you think the proposed buyout is fair?
Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Cincinnati Bell Inc. ("Cincinnati Bell" or the "Company") (NYSE: CBB) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Brookfield Infrastructure Partners L.P. ("Brookfield") (NYSE: BIP) in a transaction valued at approximately $2.6 billion. Under the terms of the agreement, shareholders of Cincinnati Bell will receive $10.50 in cash for each share of Cincinnati Bell common stock.

If you own common stock of Cincinnati Bell and purchased any shares before December 23, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra|
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com

SOURCE: Rigrodsky & Long, P.A.

ReleaseID: 571172

DEADLINE ALERT – Twitter, Inc. (TWTR) – Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $200K of Class Action and Lead Plaintiff Deadline: December 30, 2019

NEW YORK, NY / ACCESSWIRE / December 23, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Twitter, Inc. ("Twitter" or the "Company") (NYSE:TWTR) and certain of its officers, on behalf of shareholders who purchased Twitter securities between August 6, 2019 and October 23, 2019, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:www.bgandg.com/twtr.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) while Twitter represented that it "fixed" certain issues relating to user choice settings designed to target advertising were not working as intended; (2) the changes implemented to fix these issues adversely affected Twitter's ability to target advertising, including the targeting of advertising through its Mobile App Promotion ("MAP") product, which caused a material decline in advertising revenue; and (3) as a result, Twitter's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/twtr or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Twitter you have until December 30, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 571074

Social Life Network Plans Launch of New E-Commerce Platform for Hunting and Fishing Community

In 2019, retail e-commerce sales worldwide amounted to 3.53 trillion US dollars and e-retail revenues are projected to grow to 6.54 trillion US dollars by 2022.

DENVER, CO / ACCESSWIRE / December 23, 2019 / Social Life Network, Inc. (OTCQB:WDLF), announced today a major upgrade to their e-commerce social platform for the HuntPost.com hunting and fishing community, scheduled on January 1st, 2020.

In competition with retailers like Cabela's and Bass Pro Shop, HuntPost.com empowers the millions of small merchants that depend on industry trade shows to sell their goods, with an e-commerce driven social network to compete with big-box retailers who won't carry their products because they're too small to scale.

"The same way Etsy.com enabled artisans to create value from their trade, HuntPost will empower sportsmen to sell via their goods and services on our upgraded platform," says Ken Tapp, CEO of Social Life Network. "Etsy, who trades on NASDAQ, has a market cap of $5.2 billion, and services a much smaller audience of vendors and merchants than our hunting and fishing industry. This is why we've spent all of 2019 working on major upgrades for the platform in order to support HuntPost's efforts in rapidly growing their online retail audience in 2020. HuntPost is planning a Regulation A Tier 2 offering to raise up to $50M in 2020 to support their retailers, and to focus on trade show M&A. As a major licensee of our platform, they will continue to have our full support," adds Tapp.

According to Statista market research, In 2019, retail e-commerce sales worldwide amounted to 3.53 trillion US dollars and e-retail revenues are projected to grow to 6.54 trillion US dollars in 2022. https://www.statista.com/statistics/379046/worldwide-retail-e-commerce-sales/

About Social Life Network, Inc.

Social Life Network, Inc. is an artificial intelligence and blockchain powered social network and e-commerce technology company based in Denver Colorado. The social network platform meets the growing demand for social technology in the Cannabis, Residential Real Estate, and many sports verticals including Hunting & Fishing. The individual social networks service niche industries that are made up of 100's of millions of online users worldwide.

For more information, visit https://www.social-life-network.com/

Disclaimer

This news release may include forward-looking statements within the meaning of section 27A of the United States Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company's analysis of opportunities in the acquisition and development of various project interests and certain other matters. No information in this press release should be construed as any indication whatsoever of the Company's future financial results, revenues or stock price. These statements are made under the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.

Contact:

Investor Relations
IR@Social-Life-Network.com
855-933-3277

SOURCE: Social Life Network, Inc.

ReleaseID: 571169

DEADLINE ALERT – PG&E Corporation (PCG) – Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $1M of Class Action and Lead Deadline: December 24, 2019

NEW YORK, NY / ACCESSWIRE / December 23, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against PG&E Corporation ("PG&E" or the "Company") (NYSE:PCG) and certain of its officers, on behalf of shareholders who purchased PG&E securities between December 11, 2018 and October 11, 2019 (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/pcg.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) PG&E's purportedly enhanced wildfire prevention and safety protocols and procedures were inadequate to meet the challenges for which they were ostensibly designed; (2) as a result, PG&E was unprepared for the rolling power cuts the Company implemented to minimize wildfire risk; and (3) as a result, PG&E's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/pcg or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in PG&E you have until December 24, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 571073

FINAL DEADLINE ALERT – Zynerba Pharmaceuticals, Inc. (ZYNE) – Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action and Lead Deadline: December 23, 2019

NEW YORK, NY / ACCESSWIRE / December 23, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zynerba Pharmaceuticals, Inc. ("Zynerba" or the "Company") (ZYNE) and certain of its officers, on behalf of shareholders who purchased Zynerba securities between March 11, 2019, and September 17, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/zyne.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

On September 18, 2019, during pre-market hours, Zynerba issued a press release announcing results from the BELIEVE 1 Trial evaluating topical gel Zygel in children and adolescents with DEE (the "September 2019 Press Release"). While Zynerba asserted that Zygel was well-tolerated in the September 2019 Press Release, it also disclosed that, among patients enrolled in the BELIEVE 1 Trial, the rate of treatment emergent adverse events ("TEAEs") was 96%, the rate of treatment related adverse events ("TRAEs") was 60%, and there were ten patients who reported serious adverse events ("SAEs"), of which, "two SAEs (lower respiratory tract infection and status epilepticus) were determined to be possibly related to treatment." Following this news, Zynerba's stock price fell $2.46 per share, or 21.77%, to close at $8.84 per share on September 18, 2019.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/zyne or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Zynerba you have until December 23, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 571072

FINAL DEALINE ALERT – Zendesk, Inc. (ZEN) – Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action and Lead Deadline: December 23, 2019

NEW YORK, NY / ACCESSWIRE / December 23, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zendesk, Inc. ("Zendesk" or the "Company") (NASDAQ: ZEN) and certain of its officers, on behalf of shareholders who purchased Zendesk securities between February 6, 2019 and October 1, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:www.bgandg.com/zen.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zendesk's clients had been subject to data breaches dating back to 2016; (2) Zendesk was experiencing slowing demand for its SaaS offerings, particularly in Germany, the U.K. and Australia, due in large part to political uncertainty and China trade issues; (3) for the forgoing reasons, Zendesk's business metrics and financial prospects were not as strong as represented during the Class Period; and (4) as a result, Zendesk's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/zen or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Zendesk you have until December 23, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 571071

Ubique Grants 1,350,000 Options to Management and Directors

TORONTO, ON / ACCESSWIRE / December 23, 2019 / Ubique Minerals Limited ("Ubique")(CSE:UBQ) announces that, pursuant to the Company's stock option plan having an effective date of July 26, 2019, the UBQ Board has issued a total of 1,350,000 options to its seven directors and officers.

The options are issued at an exercise price of $0.075, vesting on issuance, and are exercisable up to three years commencing December 23, 2019.

The Company also announces the exercise of 100,000 previously issued options expiring in January 2020, by a Director, at an exercise price of $0.10 per share.

About Ubique Minerals Limited.

Ubique Minerals Limited is a zinc exploration company listed on the CSE (CSE:UBQ). It has focused on exploration of its 100% owned Daniel's Harbour zinc property in Newfoundland and was initially funded for two years by private equity including that from Greenbank Capital Inc (CSE:GBC and OTCMKTS:GRNBF and FRA:2TL). Ubique became a publicly listed company in September 2018. Ubique undertook one drilling program on its Daniel's Harbour zinc project in 2017 and two more drilling campaigns in 2018, and one in 2019 which were successful in delineating zinc mineralization extending from the vicinity of former mine workings. Ubique has an experienced management group with a record of multiple discoveries of deposits worldwide, and has an extensive database of historic exploration results from the Daniel's Harbour area. For more information on Ubique please contact Gerald Harper, CEO, at (416) 232-9114 or by email gharper@ubiquezinc.com or see www.ubiqueminerals.com.

More information regarding Ubique's exploration activities and results will be found on their website at www.ubiqueminerals.com.

Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business and trading in the common stock of Ubique Minerals Limited., the raising of additional capital and the future development of the business. The forward-looking information is based on certain key expectations and assumptions made by the company's management. Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Ubique can give no assurance that they will prove to be correct. These forward-looking statements are made as of the date of this press release and Ubique disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Ubique Minerals Limited

ReleaseID: 571170